ストックスクリーナーアプリを入手
8.58
0.47%
0.04
アフターアワーズ：
8.55
-0.03
-0.35%
前日終値:
$8.54
開ける：
$8.54
24時間の取引高:
766.68K
Relative Volume:
0.40
時価総額：
$888.18M
収益：
-
当期純損益:
$-135.21M
株価収益率:
-5.9954
EPS:
-1.4311
ネットキャッシュフロー:
$-114.35M
1週間 パフォーマンス:
+2.02%
1か月 パフォーマンス:
-15.80%
6か月 パフォーマンス:
-27.41%
1年 パフォーマンス:
+48.44%
1日の値動き範囲:
$8.485
$8.88
1週間の範囲:
$8.22
$8.88
52週間の値動き範囲:
$5.5148
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
名前
Oric Pharmaceuticals Inc
セクター
電話
(650) 388-5600
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.58 | 884.04M | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
437.22 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.74 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.63 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.00 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-11-20 | 開始されました | Evercore ISI | Outperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-10-31 | 開始されました | Wells Fargo | Overweight |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-02-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 開始されました | Wedbush | Outperform |
| 2023-03-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Perform |
| 2022-04-04 | アップグレード | Citigroup | Neutral → Buy |
| 2022-03-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-03-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-13 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-06 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-19 | 開始されました | Citigroup | Neutral |
| 2020-05-19 | 開始されました | Guggenheim | Buy |
| 2020-05-19 | 開始されました | JP Morgan | Overweight |
| 2020-05-19 | 開始されました | Jefferies | Buy |
すべてを表示
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Oncology company ORIC plans June talks at Jefferies, Goldman events - Stock Titan
Trading Systems Reacting to (ORIC) Volatility - Stock Traders Daily
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC Stock Chart | ORIC PHARMACEUTICALS INC (NASDAQ:ORIC) - ChartMill
User - The Chronicle-Journal
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan
Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada
Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus
Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus
Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan
Number of shareholders of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
ORIC: Oric PharmaceuticalsInteractive Chart - Zacks Investment Research
Wall Street Zen Downgrades Oric Pharmaceuticals (NASDAQ:ORIC) to Strong Sell - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A 135.75% Potential Upside for Investors in the Biotech Sector - DirectorsTalk Interviews
Q2 EPS Estimate for Oric Pharmaceuticals Lowered by Analyst - MarketBeat
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $15 to $25 - Moomoo
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00 - MarketBeat
ORIC Pharmaceuticals Q1 2026 Financial Report and Forward-Looking Statements - Minichart
MSN Money - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Pharmaceuticals (NASDAQ: ORIC) lifts cash to $419.7M as R&D ramps - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - The Manila Times
ORIC (NASDAQ: ORIC) details Q1 2026 loss and Phase 3 cancer plans - Stock Titan
Cancer drug developer picks Phase 3 dose, has cash into late 2028 - Stock Titan
BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million - TradingView
Oric Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new ORIC hires receive 216,000 options and 35,000 RSUs - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | NDAQ:ORIC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC ... - Bluefield Daily Telegraph
Oric Pharmaceuticals Inc (ORIC) 財務データ
収益
当期純利益
現金流量
EPS
0.29%
0.81%
大文字化:
|
ボリューム (24 時間):